Skip to content

Study on the reduction of cardiac toxicity in children with aplastic anemia undergoing haploidentical hematopoietic stem cell transplantation pretreatment regimen containing Thiotepa Injection

Study on the reduction of cardiac toxicity in children with aplastic anemia undergoing haploidentical hematopoietic stem cell transplantation pretreatment regimen containing Thiotepa Injection

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600120496
Enrollment
Unknown
Registered
2026-03-16
Start date
2024-11-29
Completion date
Unknown
Last updated
2026-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aplastic anemia in children

Interventions

Children aplastic anemia observation group:None

Sponsors

Peking University People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Years to 18 Years

Inclusion criteria

Inclusion criteria: 1.Children with aplastic anemia and two or more high-risk factors for heart damage; 2. Age: 1-18 years old, gender not limited; 3.There are suitable haploidentical donors available; 4. No uncontrolled current infections (new infections, body temperature still above 38 ° C after 72 hours of broad-spectrum antibiotics, excluding other non infectious factors);

Exclusion criteria

Exclusion criteria: 1.Poor compliance of patients or family members; 2.The supplier has application mobilization agents and/or collection taboos;

Design outcomes

Primary

MeasureTime frame
+100d transplant related mortality rate after allo-HSCT;

Secondary

MeasureTime frame
Incidence of cardiac damage during conditioning;Transplant-related mortality at 1 and 3 years after transplantation;The 1-year and 3-year OS, FFS(failure free survival), and engraftment were observed Incidence of infection (including viral infection), acute/chronic GVHD;

Countries

China

Contacts

Public ContactCheng Yifei

Peking University People's Hospital

chengyifei182@sina.com+86 10 8832 6666

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 3, 2026